Disc Medicine After The CRL: Risk Now Rests On APOLLO

2026-02-17 10:40:09 ET

Thesis

As you know by now from the 21% stock slide, the FDA has issued a CRL to Disc Medicine Inc. ( IRON ) for bitopertin. However, on the surface, it appears to be more of a regulatory disagreement and not about whether the drug actually lowers its biochemical target. So it seems more about whether that biomarker itself reliably predicts real clinical benefit. The issue was in the subjectivity of whether patients showed a real lifestyle benefit. As I will explain, what it came down to was that different patients experienced or even started with different levels of sunlight exposure they were comfortable with. The result is that the FDA has deemed the AURORA and BEACON not sufficient and has indicated the need to see the results of the ongoing Phase 3 APOLLO study. Conveniently, in this press release, management has told us the APOLLO enrollment and progress are several months ahead of schedule. So we can expect to see results sometime before the end of the year....

Read the full article on Seeking Alpha

For further details see: